Efficacy and cost-effectiveness of early antiretroviral therapy and partners’ pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study

Table 3 Cost-utility ratio per case in 6 scenarios over 36 months post-infection

Scenario	Cost ($)	Averted HIV infection	QALY	CUR
Scenarios based on observed data
Non-ART	3,540	NA	NA	NA
Standard-ART	6,063	0.09	0.21	28,272
Early-ART	10,024	0.34	0.78	12,864
Scenarios based on observed and hypothetical data
Non-ART plus partners’ PrEP	40,974	0.38	0.87	47,321
Standard-ART plus partners’ PrEP	33,973	0.39	0.89	38,287
Early-ART plus partners’ PrEP	15,872	0.41	0.94	16,817

$ U.S. dollars, QALY quality-adjusted life-years, CUR cost-utility ratio, ART antiretroviral therapy, NA not applicable, PrEP pre-exposure prophylaxis

ISSN: 1471-2334